New discovery of tuberculosis pathogenic mechanism provides new targets for drug development

Data show that for 40 years, TB treatment drugs limited to isoniazid, lifu equality is known as the "little miga rifle" several combinations, with the use of older drugs in the world for many years a large number or even improper use, drug efficacy is decreasing, drug resistance problems are inevitable"the core problem is that the pathogenesis and drug resistance mechanisms of infection are not fully clear." Gobosi believes that tuberculosis prevention and control in basic research, diagnostic methods and treatment challenges, especially the basic research is weak, the pathogenesis is not fully clearGobossaid, when the human body infected with TB bacteria, TB bacteria can secrete the toxic factor Rv0222, and Rv0222 using the human protein modification system after secondary processing, can effectively resist attacks from the human immune system, resulting in TB bacteria from the human immune system successfully escape and disease"For example, the protein 'slyly' uses the body's own 'spear' (protein molecules) to attack the body's own 'shield' (immune system), thus avoiding attacks on the body's immune system, and eventually successfully infecting tbHe saidToday, a major breakthrough has been made in the basic research of TB bacteria, and the next step is to further transform the research results and apply them to the clinic"We hope to lead the team to focus on the field of TB translational medicine research, make a series of original breakthroughs, and actively promote the transformation of these basic research results into clinical treatment and anti-TB drugs and vaccine developmentGoppel doctrineProfessor Zhao Guoping, a member of theChinese Academy of Sciences, and Professor Xiao Ping, former chairman of the Chinese Medical Association's Tb Credit Association and chief clinical consultant expert on tuberculosis, said that the study fully expounded the immune escape mechanism of TB bacteria using human components to resist human attack, and the researchers, through protein structure analysis and functional exploration, accurately pointed out that Rv0222 toxic protein is the 76-bit lysine on its 76-bit lysine, K-11 ubiquity modification, can be used to provide a new anti-TB drug.